Abstract
Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.
| Original language | English |
|---|---|
| Pages (from-to) | 11-24 |
| Number of pages | 14 |
| Journal | Drug Discovery Today |
| Volume | 18 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - Jan 2013 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. / Favoni, Roberto E.; Alama, Angela.
In: Drug Discovery Today, Vol. 18, No. 1-2, 01.2013, p. 11-24.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout
AU - Favoni, Roberto E.
AU - Alama, Angela
PY - 2013/1
Y1 - 2013/1
N2 - Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.
AB - Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.
UR - http://www.scopus.com/inward/record.url?scp=84871928651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871928651&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2012.07.011
DO - 10.1016/j.drudis.2012.07.011
M3 - Article
C2 - 22885521
AN - SCOPUS:84871928651
VL - 18
SP - 11
EP - 24
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 1-2
ER -